|Articles|February 13, 2023
Novavax COVID Vaccine 140 Million Dose Order Canceled by Japan, Takeda Reveals
Takeda's partnership with Novavax to manufacture 150 million doses of COVID-19 vaccine has been heavily impacted.
Advertisement
In 2021, Takeda announced a partnership with Novavax to manufacture 150 million doses of the Nuvaxovid COVID-19 vaccine; however, the Japanese government has canceled its order for the remaining 141.76 million doses due to low demand.
Japan's cancellation of the Novavax vaccine order will not significantly impact Takeda's finances and the company is not altering its full-year consolidated forecasts.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
2
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
3
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
4
FDA’s Shift Signals a New Era for Data-Driven Drug Development
5